Organization
HaaPACS GmbH, Schriesheim, Germany
1 abstract
Abstract
A MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BARICITINIB, TARGETED SYNTHETIC OR BIOLOGIC DISEASE-MODIFYING THERAPIES: 12 MONTH TIME TO DISCONTINUATION, EFFECTIVENESS AND PATIENT REPORTED OUTCOME DATA FROM THE EUROPEAN COHORTOrg: Schlosspark Klinik, Department of Internal Medicine and Rheumatology, Berlin, Germany, Charité Universitätsmedizin, Department of Rheumatology and Clinical Immunology, Indianapolis, United States of America, IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milan, Italy, University of Florence and Division of Rheumatology AOUC, Department of Experimental and Clinical Rheumatology, Florence, Italy, Monash University and Emeritus Research, Cabrini Hospital, Melbourne, Australia,